Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001;2000(2):CD002987.
doi: 10.1002/14651858.CD002987.

Troleandomycin as an oral corticosteroid steroid sparing agent in stable asthma

D J Evans  1 , P Cullinan, D M Geddes
Affiliations

Troleandomycin as an oral corticosteroid steroid sparing agent in stable asthma

D J Evans et al. Cochrane Database Syst Rev. 2001.

Abstract

Background: Patients with chronic severe asthma are often dependent on the long term prescription of oral corticosteroids. The use of steroids is associated with serious side effects. Physicians treating such patients continue to search for alternative therapies that reduce the need for chronic dosing with oral steroids. troleandomycin is a compound that is established as an effective antibiotic but may also have non antibacterial actions that may be useful in the treatment of asthma.

Objectives: The objective of this review was to assess the effects of adding troleandomycin to oral steroids in the treatment of chronic steroid dependent asthmatics.

Search strategy: The Cochrane Airways Group trials register and reference lists of identified articles were searched.

Selection criteria: Randomised trials looking at the addition of troleandomycin compared to placebo in adult steroid dependent asthmatics.

Data collection and analysis: Trial quality was assessed and data extraction was carried out by two reviewers independently. Study authors were contacted for missing information.

Main results: Three trials fulfilled the criteria for inclusion in the review and a total of 112 patients were recruited into these studies. Data from 90 patients were analysed. There was no treatment effect for troleandomycin in terms of steroid dose reduction (SMD -0.29, 95% CI -0.75, 0.17). For measures of lung function a meta-analysis of data derived from two of the included studies showed no benefits for added troleandomycin (SMD 0.06 95% CI -0.8, 0.9).

Reviewer's conclusions: There is insufficient evidence to support the use of troleandomycin in the treatment of steroid dependent asthma.

PubMed Disclaimer

Conflict of interest statement

None

Similar articles

See all similar articles

Cited by

References

References to studies included in this review

Ball 1990 {published data only}
    1. Ball BD, Hill MR, Brenner M, Sanks R, Szefler SJ. Effect of low‐dose troleandomycin on glucocorticoid pharmacokinetics and airway hyperresponsiveness in severely asthmatic children. Annals of Allergy 1990;65:37‐45. - PubMed
Kamada 1993 {published data only}
    1. Kamada AK, Hill MR, Ikle DN, Brenner M, Szefler SJ. Efficacy and safety of low‐dose troleandomycin therapy in children with severe, steroid‐requiring asthma. Journal of Allergy and Clinical Immunology 1993;91:873‐82. - PubMed
Nelson 1993 {published data only}
    1. Nelson HS, Hamilos DL, Corsello PR, Levesque NV, Buchmeier AD, Bucher BL. A double‐blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. American Review of Respiratory Disease 1993;147:398‐404. - PubMed

References to studies excluded from this review

Andrade 1983 {published data only}
    1. Andrade WP, Renard RL, Nelson HS. The effect of methylprednisolone (MP) and troleandomycin (TAO) alone and in combination on bronchial sensitivity to methacholine (MC). Annals of Allergy 1983;51(5):515‐7. - PubMed
Eitches 1985 {published data only}
    1. Eitches RW, Rachelefsky GS, Katz RM, Mendoza GR, Siegel SC. Methylprednisolone and troleandomycin in the treatment of steroid‐dependent asthmatic children. American Journal of Diseases of Childhood 1985;139:264‐8. - PubMed
Flotte 1991 {published data only}
    1. Flotte TR, Loughlin GM. Benefits and complications of troleandomycin (TAO) in young children with steroid‐dependent asthma. Pediatric Pulmonology 1991;10:178‐82. - PubMed
Itkin 1970 {published data only}
    1. Itkin IH, Menzel ML. The use of macrolide antibiotic substances in the treatment of asthma. Journal of Allergy 1970;45:146‐62. - PubMed
Menz 1990 {published data only}
    1. Menz G, Rothe T, Schmitt M, Schmitz M, Hauser F, Haack D, et al. Experiences with a combination therapy of methylprednisolone and troleandomycin in severe bronchial asthma requiring high‐dose corticoids [Erfahrungen mit einer Kombinationstherapie von Methylprednisolon und Troleandomycin (TAO) bei schwerem, hochkortikoidbedurftigem Asthma bronchiale]. Pneumologie 1990;44(Suppl 1):238‐40. - PubMed
Rosenberg 1991 {published data only}
    1. Rosenberg SM, Gerhard H, Grunstein MM, Schramm CM. Use of TAO without methylprednisolone in the treatment of asthma. Chest 1991;100:849‐50. - PubMed
Siracusa 1993 {published data only}
    1. Siracusa A, Brugnami G, Fiordi T, Areni S, Sverini C, Marabini A. Troleandomycin in the treatment of difficult asthma. Journal of Allergy and Clinical Immunology 1993;92:677‐82. - PubMed
Spector 1974 {published data only}
    1. Spector SL, Katz FH, Farr RS. Troleandomycin; effectiveness in steroid dependent asthma and bronchitis. Journal of Allergy and Clinical Immunology 1974;54(6):367‐79.
Wald 1986 {published data only}
    1. Wald JA, Friedman BF, Farr RS. An improved protocol for the use of troleandomycin (TAO) in the treatment of steroid requiring asthma. Journal of Allergy and Clinical Immunology 1986;78:36‐43. - PubMed
Zeiger 1980 {published data only}
    1. Zeiger RS, Schatz M, Sperling W, Simon RA, Stevenson DD. Efficacy of troleandomycin in outpatients with severe, corticosteroid‐dependent asthma. Journal of Allergy and Clinical Immunology 1980;66:438‐46. - PubMed

Publication types

MeSH terms